Harvard Bioscience, Inc. (HBIO) Analysts See $0.04 EPS

July 16, 2018 - By Lisa Delgado

Harvard Bioscience, Inc. (NASDAQ:HBIO) LogoInvestors sentiment increased to 2.28 in 2018 Q1. Its up 0.96, from 1.32 in 2017Q4. It improved, as 4 investors sold Harvard Bioscience, Inc. shares while 14 reduced holdings. 22 funds opened positions while 19 raised stakes. 23.08 million shares or 4.25% more from 22.13 million shares in 2017Q4 were reported.
Ameriprise Fin invested 0% in Harvard Bioscience, Inc. (NASDAQ:HBIO). 769,917 are owned by Bridgeway Mgmt Inc. Macquarie Group invested in 110,407 shares or 0% of the stock. Goldman Sachs Grp Inc holds 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 121,847 shares. Dimensional Fund Advsr Limited Partnership accumulated 1.87 million shares. Vanguard Grp Incorporated Inc holds 0% or 1.36 million shares in its portfolio. Blackrock owns 1.43 million shares or 0% of their US portfolio. Sei Investments, a Pennsylvania-based fund reported 1,383 shares. Invesco Limited stated it has 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Element Management Limited Liability Company has invested 0% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Axa invested 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). First Light Asset Mgmt Ltd reported 5.44 million shares stake. Bank & Trust Of America De reported 147,977 shares stake. Granahan Invest Mgmt Ma holds 0.35% or 961,647 shares in its portfolio. Meristem Limited Liability Partnership holds 13,444 shares.

Since March 7, 2018, it had 0 buys, and 5 selling transactions for $2.11 million activity. Another trade for 35,054 shares valued at $161,599 was sold by UVEGES GEORGE. Duchemin Jeffrey sold $393,963 worth of Harvard Bioscience, Inc. (NASDAQ:HBIO) on Thursday, March 8.

Analysts expect Harvard Bioscience, Inc. (NASDAQ:HBIO) to report $0.04 EPS on July, 26.They anticipate $0.03 EPS change or 300.00 % from last quarter’s $0.01 EPS. HBIO’s profit would be $1.44 million giving it 32.19 P/E if the $0.04 EPS is correct. After having $0.01 EPS previously, Harvard Bioscience, Inc.’s analysts see 300.00 % EPS growth. It closed at $5.15 lastly. It is up 88.04% since July 16, 2017 and is uptrending. It has outperformed by 75.47% the S&P500.

Harvard Bioscience, Inc. (NASDAQ:HBIO) Ratings Coverage

Among 2 analysts covering Harvard Bioscience (NASDAQ:HBIO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harvard Bioscience had 2 analyst reports since January 24, 2018 according to SRatingsIntel.

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company has market cap of $185.30 million. The firm offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It currently has negative earnings. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands.

Another recent and important Harvard Bioscience, Inc. (NASDAQ:HBIO) news was published by Nasdaq.com which published an article titled: “Harvard Bioscience Subsidiary Data Sciences International Launches Two Telemetry Implants For Measuring …” on June 20, 2018.

Harvard Bioscience, Inc. (NASDAQ:HBIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.